Epidermal growth factor receptor EGFR–targeted drugs represent a cornerstone in the treatment of advanced non–small cell lung cancer (NSCLC) harboring EGFR gene mutations. EGFR mutations are a major category of lung cancer biomarkers. NSCLC is the most common subtype of…
In today’s increasingly competitive global pharmaceutical landscape, choosing a reputable pharmaceutical wholesaler has become a critical strategic decision for pharmaceutical companies, healthcare institutions, and medical traders seeking sustainable long-term growth. A reliable partner not only ensures stable product supply but…
Source: DengYueMed On October 18, Chen Yuqing, Chairman of Fosun Pharma, stated at an event that China’s innovative drug industry has made a qualitative leap over the past decade. Since 2014, China’s share of global R&D pipelines for innovative drugs…
On May 6, the U.S. government announced plans to unveil new pharmaceutical tariff measures within the next two weeks. Can innovative drugs accelerate overseas expansion by 2025? Under current U.S. policy, pharmaceuticals are classified as tariff-exempt goods, so the potential…
In the first half of 2025, China’s innovative drug license-out deals surpassed USD 15 billion, marking a 40% year-over-year increase. Antibody-drug conjugates (ADCs) and bispecific antibodies now account for over 60% of all outbound transactions — signaling a new wave…
The Prescription Drug User Fee Act (PDUFA) date marks the deadline by which the U.S. Food and Drug Administration (FDA) must complete its review of a New Drug Application (NDA) or Biologics License Application (BLA). The standard review cycle is…
Melanoma cancer is a type of skin cancer that begins in the pigment-producing cells called melanocytes. When these cells grow uncontrollably, they can form tumors and, in advanced stages, spread to other parts of the body. Although melanoma cancer accounts…
Lymphoma cancer is a type of cancer that begins in the lymphatic system, where abnormal lymphocytes (a kind of white blood cell) grow uncontrollably and form tumors that can spread throughout the body. It is one of the most common…
DengYueMed reports the latest developments in global new drug approvals and submissions for early September 2025. Newly Approved Drugs 1. Lecanemab Subcutaneous Auto-Injector (IQLIK™) 2. Inebilizumab Injection (XinYue®) 3. Denosumab Injection (HLX14) 4. Teplizumab Injection 5. Enarodustat Tablets (Ennaro®) 6.…
Source: Dengyuemed | September 27, 2025 | Category: Pharmaceuticals As a Hong Kong drug wholesale distributor, we closely follow China Medical’s progress across innovative drug development, biosimilars, and global expansion. By tracking these breakthroughs — from first-in-class approvals to Phase…
